Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for nephrotic glomerulonephritis
ISRCTN16948923Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in nephrosis and focal segmental glomerulosclerosis (FSGS) comparing Rituximab + prednisolone with Placebo + prednisolone (2 arms). Primary endpoint: Time from partial or complete remission to relapse of nephrotic syndrome. Started Jul 2019; status: completed.
02
Drugs
rituximab
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ISRCTN16948923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16948923.